Skip to content

JBIO JBIO Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Vor Biopharma logo
Vor BiopharmaVOR

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's operating lease right-of-use assets in other assets?
JBIO (JBIO) reported operating lease right-of-use assets in other assets of $690K in Q1 2026.
How has JBIO's operating lease right-of-use assets in other assets changed year-over-year?
JBIO's operating lease right-of-use assets in other assets increased by 336.7% year-over-year, from $158K to $690K.
What is the long-term trend for JBIO's operating lease right-of-use assets in other assets?
Over 4 years (2021 to 2025), JBIO's operating lease right-of-use assets in other assets has grown at a 7.6% compound annual growth rate (CAGR), from $542K to $726K.